| Pharmacokinetic Modelling Physiomics simulates the drug concentration-time profiles in different target organs by using the sophisticated PK-SimŽ software. PK-SimŽ uses the latest and most sophisticated physiology-based pharmacokinetic software technology to give an accurate whole body simulation that is pre-calibrated for mouse, rat, dog and human, allowing detailed organ levels of a drug to be predicted. This enables the prediction, interpretation and extrapolation of pharmacokinetic concentration-time profiles. It can be specifically customized to individual pre clinical experiments and used to predict individual patient or population outcomes. Hence, it is a very powerful tool for the analysis of clinical data sets, particularly if there is high variability. PK-Sim can also be used to test the scaleable of Phase 0 (microdose) studies. Whole body model
PK-Sim allows the fate of drugs in the body to be described on the basis of a mathematical representation of the ADME properties of the molecule. It is the only commercial solution that integrates absorption and distribution in a whole body model. PK-Sim is a universal model providing detailed descriptions of the important active and passive processes. PK-Sim's physiology-based pharmacokinetic (PBPK) whole-body model allows prediction of oral absorption as well as drug concentration profiles in relevant organs. PK-Sim allows the calculation of model parameters such as permeability and organ/plasma partition coefficients from physicochemical data with built-in mechanistic models. The software can be used to predict pharmacokinetics of oral absorption in early phases of drug research. It can be extended to the treatment of problems in later phases of clinical development either in a prospective way or to explain experimental findings. In the research phase PK-Sim can predict PK properties of drugs from in vitro data identifying critical issues such as poor adsorption or inadequate tissue distribution improving the selection process. In the pre-clinical phase it can simulate animal experiments reducing the total number of animal studies required shortening this phase. The software can make cross-species prediction and can be used to predict initial doses in humans reducing the risk of adverse events, reducing the risk of repeating expensive trials and potentially reducing the numbers of human volunteers required. It can also make predictions about possible variability in the clinical trial phases enabling determination of optimal number of patients required for a successful outcome. For more information please contact us and read the frequently asked questions.
|
|
|
|
